Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
- PMID: 21115397
- PMCID: PMC3075964
- DOI: 10.1016/j.molmed.2010.10.002
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
Abstract
Tuberous sclerosis (TSC) is a genetic disorder caused by heterozygous mutations in the TSC1 or TSC2 genes and is associated with autism spectrum disorders (ASD) in 20-60% of cases. In addition, altered TSC/mTOR signaling is emerging as a feature common to a subset of ASD. Recent findings, in animal models, show that restoration of the underlying molecular defect can improve neurological dysfunction in several of these models, even if treatment is initiated in adult animals, suggesting that pathophysiological processes in the mature brain contribute significantly to the overall neurological phenotype in these models. These findings suggest that windows for therapeutic intervention in ASD could be wider than thought previously.
Published by Elsevier Ltd.
Figures
References
-
- European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–1315. - PubMed
-
- van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–808. - PubMed
-
- Osborne JP, et al. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125–127. - PubMed
-
- Crino PB, et al. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–1356. - PubMed
-
- Osborne JP, et al. Non-penetrance in tuberous sclerosis. Lancet. 2000;355:1698. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
